Dasatinib (Standalone Senolytic)

Dasatinib represents one of the most researched pharmaceutical senolytics, originally developed as a cancer therapy targeting chronic myeloid leukemia. Research suggests this tyrosine kinase inhibitor can selectively eliminate senescent cells—aged, damaged cells that contribute to inflammation and age-related diseases. Early human studies indicate potential benefits for physical function, lung fibrosis, and other age-related conditions when used in intermittent dosing protocols.

The drug works by disrupting survival pathways that senescent cells rely on to resist natural cell death, effectively allowing the body to clear these problematic cells. Most senolytic protocols combine dasatinib with quercetin (D+Q), as studies suggest this combination targets a broader range of senescent cell types than either compound alone. Clinical trials have used intermittent dosing—typically 3 consecutive days per month—rather than continuous treatment.

While promising, dasatinib carries significant risks as a potent chemotherapy drug, including potential for bleeding complications, infections due to immune suppression, and cardiovascular effects. Research indicates the senolytic field is moving rapidly, with ongoing trials examining optimal dosing, patient selection, and long-term safety profiles. The intervention requires careful medical supervision and regular monitoring of blood counts and organ function.